当前位置： SCI文献检索 > Alzheimers Research & Therapy期刊下所有文献 > Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Abstract：

:The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of dementia (non-AD). The concentration ratio of Aβ42 to Aβ40 (Aβ42/40 Ratio) has been suggested to be superior to the concentration of Aβ42 alone when identifying patients with AD. This article reviews the available evidence on the use of the CSF Aβ42/40 ratio in the diagnosis of AD. Based on the body of evidence presented herein, it is the conclusion of the current working group that the CSF Aβ42/40 ratio, rather than the absolute value of CSF Aβ42, should be used when analysing CSF AD biomarkers to improve the percentage of appropriately diagnosed patients.

journal_name

Alzheimers Res Ther

journal_title

Alzheimer's research & therapy

authors

Hansson O,Lehmann S,Otto M,Zetterberg H,Lewczuk P

doi

10.1186/s13195-019-0485-0

subject

Has Abstract

pub_date

2019-04-22 00:00:00

pages

34

issue

1

issn

1758-9193

pii

10.1186/s13195-019-0485-0

journal_volume

11

pub_type

杂志文章,评审

相关文献

Alzheimers Research & Therapy文献大全
  • Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.

    abstract：BACKGROUND:Kallikrein 6 (KLK6) is known to be an age-related protease expressed at high levels in the central nervous system. It was previously shown to be involved in proteolysis of extracellular proteins implicated in neurodegenerative diseases such as Alzheimer's disease (AD), prompting validation of KLK6 as a poten...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0336-4

    authors： Patra K,Soosaipillai A,Sando SB,Lauridsen C,Berge G,Møller I,Grøntvedt GR,Bråthen G,Begcevic I,Moussaud S,Minthon L,Hansson O,Diamandis EP,White LR,Nielsen HM

    更新日期：2018-01-29 00:00:00

  • The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact.

    abstract：INTRODUCTION:The Third National Alzheimer Plan (2008-2012) was a major public health initiative in France that included €200 million of funding for research in Alzheimer disease and related disorders (AD). The aim of this study was to document trends in French academic output in AD following the implementation of the p...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-015-0144-z

    authors： Haeffner-Cavaillon N,Devos P,Ledoux S,Ménard J

    更新日期：2015-09-26 00:00:00

  • Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

    abstract：:Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and molecular studies of autosomal-dominant Alzheimer's disease, highlighting the similarities and differences between...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt59

    authors： Bateman RJ,Aisen PS,De Strooper B,Fox NC,Lemere CA,Ringman JM,Salloway S,Sperling RA,Windisch M,Xiong C

    更新日期：2011-01-06 00:00:00

  • The association of vascular disorders with incident dementia in different age groups.

    abstract：BACKGROUND:There is increasing evidence that dementia risk associated with vascular disorders is age dependent. Large population-based studies of incident dementia are necessary to further elucidate this effect. Therefore, the aim of the present study was to determine the association of vascular disorders with incident...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0496-x

    authors： Legdeur N,van der Lee SJ,de Wilde M,van der Lei J,Muller M,Maier AB,Visser PJ

    更新日期：2019-05-17 00:00:00

  • Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.

    abstract：BACKGROUND:Determination of β-amyloid (Aβ) positivity and likelihood of underlying Alzheimer's disease (AD) relies on dichotomous biomarker cut-off values. Individuals with mild cognitive impairment (MCI) and Aβ within the normal range may still have a substantial risk of developing dementia, primarily of Alzheimer typ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0557-1

    authors： Rosenberg A,Solomon A,Jelic V,Hagman G,Bogdanovic N,Kivipelto M

    更新日期：2019-12-05 00:00:00

  • Subcortical hyperintensity volumetrics in Alzheimer's disease and normal elderly in the Sunnybrook Dementia Study: correlations with atrophy, executive function, mental processing speed, and verbal memory.

    abstract：INTRODUCTION:Subcortical hyperintensities (SHs) are radiological entities commonly observed on magnetic resonance imaging (MRI) of patients with Alzheimer's disease (AD) and normal elderly controls. Although the presence of SH is believed to indicate some form of subcortical vasculopathy, pathological heterogeneity, me...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt279

    authors： Ramirez J,McNeely AA,Scott CJ,Stuss DT,Black SE

    更新日期：2014-08-11 00:00:00

  • In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

    abstract：BACKGROUND:Imaging agents capable of quantifying the brain's tau aggregates will allow a more precise staging of Alzheimer's disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0402-y

    authors： Pascoal TA,Shin M,Kang MS,Chamoun M,Chartrand D,Mathotaarachchi S,Bennacef I,Therriault J,Ng KP,Hopewell R,Bouhachi R,Hsiao HH,Benedet AL,Soucy JP,Massarweh G,Gauthier S,Rosa-Neto P

    更新日期：2018-07-31 00:00:00

  • Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals.

    abstract：BACKGROUND:Amyloid pathology, which is one of the characteristics of Alzheimer's disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ1-42 is evident in AD, and the CSF ratio Aβ42/Aβ40 has recentl...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00696-1

    authors： Lehmann S,Dumurgier J,Ayrignac X,Marelli C,Alcolea D,Ormaechea JF,Thouvenot E,Delaby C,Hirtz C,Vialaret J,Ginestet N,Bouaziz-Amar E,Laplanche JL,Labauge P,Paquet C,Lleo A,Gabelle A,Alzheimer’s Disease Neuroimaging Initi

    更新日期：2020-10-02 00:00:00

  • Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

    abstract：BACKGROUND:Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS:Here we describe the first clinical study with BAN2401. Safety and tolerability were...

    journal_title：Alzheimer's research & therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1186/s13195-016-0181-2

    authors： Logovinsky V,Satlin A,Lai R,Swanson C,Kaplow J,Osswald G,Basun H,Lannfelt L

    更新日期：2016-04-06 00:00:00

  • Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.

    abstract：:Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson's disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Symptomatic treatments for LBD, which can include cognitive, neuropsychiatric, autonomic, sleep, and motor features...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-020-00703-5

    authors： Goldman JG,Forsberg LK,Boeve BF,Armstrong MJ,Irwin DJ,Ferman TJ,Galasko D,Galvin JE,Kaufer D,Leverenz J,Lippa CF,Marder K,Abler V,Biglan K,Irizarry M,Keller B,Munsie L,Nakagawa M,Taylor A,Graham T

    更新日期：2020-10-29 00:00:00

  • Systematic reviews on behavioural and psychological symptoms in the older or demented population.

    abstract：INTRODUCTION:Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demented and demented population. METHODS:We have undertaken a systematic review of reviews to give a ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt131

    authors： van der Linde RM,Stephan BC,Savva GM,Dening T,Brayne C

    更新日期：2012-07-11 00:00:00

  • A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.

    abstract：INTRODUCTION:There is a great need for quick tests that identify treatment response in Alzheimer's disease (AD) to determine who benefits from the treatment. In this study, A Quick Test of cognitive speed (AQT) was compared with the mini-mental state examination (MMSE) in the evaluation of treatment outcome in AD. MET...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt53

    authors： Palmqvist S,Minthon L,Wattmo C,Londos E,Hansson O

    更新日期：2010-10-15 00:00:00

  • Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).

    abstract：BACKGROUND:The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain pathology can be visualized in the cerebrospinal fluid (CSF) by protein profiling. It is clear that the fiel...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-017-0265-7

    authors： Vanderstichele H,Demeyer L,Janelidze S,Coart E,Stoops E,Mauroo K,Herbst V,François C,Hansson O

    更新日期：2017-06-06 00:00:00

  • Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?

    abstract：:The strongest known risk factors for late-onset Alzheimer disease (LOAD) remain a positive family history and the APOE epsilon4 allele. van Exel and colleagues used these known risk factors to identify high- and low-risk samples of middle-aged persons in whom they compared levels of inflammatory and vascular risk fact...

    journal_title：Alzheimer's research & therapy

    pub_type： 社论

    doi：10.1186/alzrt29

    authors： Tan ZS,Seshadri S

    更新日期：2010-04-12 00:00:00

  • Correction to: Neurexin 3 transmembrane and soluble isoform expression and splicing haplotype are associated with neuron inflammasome and Alzheimer's disease.

    abstract：:Following publication of the original article [1], the authors reported that Fig. 6 contains a mistake. The Fig. 6F is a duplicate of Fig. 6E of Braak 5. ...

    journal_title：Alzheimer's research & therapy

    pub_type： 已发布勘误

    doi：10.1186/s13195-019-0493-0

    authors： Hishimoto A,Pletnikova O,Lang DL,Troncoso JC,Egan JM,Liu QR

    更新日期：2019-05-07 00:00:00

  • Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.

    abstract：BACKGROUND:Amyloid-β 1-42 (Aβ1-42) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer's disease (AD). Reduced levels of Aβ1-42 are indicative of AD, but significant variation in the absolute concentrations of this analyte has been described for both healthy and diseased populations. Preanal...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0445-0

    authors： Schauer SP,Mylott WR Jr,Yuan M,Jenkins RG,Rodney Mathews W,Honigberg LA,Wildsmith KR

    更新日期：2018-11-28 00:00:00

  • Potential sources of interference on Abeta immunoassays in biological samples.

    abstract：:Therapeutic products that depend on the use of an in vitro diagnostic biomarker test to confirm their effectiveness are increasingly being developed. Use of biomarkers is particularly meaningful in the context of selecting the patient population where the therapeutic treatment is believed to be efficacious (patient en...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/alzrt142

    authors： Vanderstichele H,Stoops E,Vanmechelen E,Jeromin A

    更新日期：2012-10-17 00:00:00

  • Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey.

    abstract：INTRODUCTION:The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheim...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0525-9

    authors： Bertens D,Vos S,Kehoe P,Wolf H,Nobili F,Mendonça A,van Rossum I,Hort J,Molinuevo JL,Heneka M,Petersen R,Scheltens P,Visser PJ

    更新日期：2019-08-22 00:00:00

  • Cognitive training and brain stimulation in prodromal Alzheimer's disease (AD-Stim)-study protocol for a double-blind randomized controlled phase IIb (monocenter) trial.

    abstract：BACKGROUND:Given the growing older population worldwide, and the associated increase in age-related diseases, such as Alzheimer's disease (AD), investigating non-invasive methods to ameliorate or even prevent cognitive decline in prodromal AD is highly relevant. Previous studies suggest transcranial direct current stim...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00692-5

    authors： Thams F,Kuzmina A,Backhaus M,Li SC,Grittner U,Antonenko D,Flöel A

    更新日期：2020-11-07 00:00:00

  • Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

    abstract：BACKGROUND:Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-016-0170-5

    authors： Podhorna J,Krahnke T,Shear M,Harrison JE,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期：2016-02-12 00:00:00

  • Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

    abstract：BACKGROUND:Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling. METHODS:We convened a ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-017-0261-y

    authors： Grill JD,Apostolova LG,Bullain S,Burns JM,Cox CG,Dick M,Hartley D,Kawas C,Kremen S,Lingler J,Lopez OL,Mapstone M,Pierce A,Rabinovici G,Roberts JS,Sajjadi SA,Teng E,Karlawish J

    更新日期：2017-05-04 00:00:00

  • Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.

    abstract：INTRODUCTION:Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It reduces pathology in transgenic models of Alzheimer's disease (AD) and is a promising candidat...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt146

    authors： Ringman JM,Frautschy SA,Teng E,Begum AN,Bardens J,Beigi M,Gylys KH,Badmaev V,Heath DD,Apostolova LG,Porter V,Vanek Z,Marshall GA,Hellemann G,Sugar C,Masterman DL,Montine TJ,Cummings JL,Cole GM

    更新日期：2012-10-29 00:00:00

  • Older patients are still under-represented in clinical trials of Alzheimer's disease.

    abstract：BACKGROUND:The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research are systematically younger than those in the general population. We examined the age gap between pa...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-016-0201-2

    authors： Banzi R,Camaioni P,Tettamanti M,Bertele' V,Lucca U

    更新日期：2016-08-12 00:00:00

  • Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.

    abstract：BACKGROUND:Whether age at onset influences Alzheimer's disease (AD) progression and the effectiveness of cholinesterase inhibitor (ChEI) therapy is not clear. We aimed to compare longitudinal cognitive and global outcomes in ChEI-treated patients with early-onset Alzheimer's disease (EOAD) versus late-onset Alzheimer's...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,多中心研究

    doi：10.1186/s13195-017-0294-2

    authors： Wattmo C,Wallin ÅK

    更新日期：2017-08-31 00:00:00

  • Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

    abstract：BACKGROUND:The Centiloid scale has been developed to standardize measurements of amyloid PET imaging. Reference cut-off values of this continuous measurement enable the consistent operationalization of decision-making for multicentre research studies and clinical trials. In this study, we aimed at deriving reference Ce...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0478-z

    authors： Salvadó G,Molinuevo JL,Brugulat-Serrat A,Falcon C,Grau-Rivera O,Suárez-Calvet M,Pavia J,Niñerola-Baizán A,Perissinotti A,Lomeña F,Minguillon C,Fauria K,Zetterberg H,Blennow K,Gispert JD,Alzheimer’s Disease Neuroimaging Init

    更新日期：2019-03-21 00:00:00

  • The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study.

    abstract：INTRODUCTION:Weight loss has been described in 20% to 45% of patients with Alzheimer's disease (AD) and has been associated with adverse outcomes. Various mechanisms for weight loss in AD patients have been proposed, though none has been proven. This study aimed to elucidate a mechanism of weight loss in AD patients by...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-015-0098-1

    authors： Droogsma E,van Asselt D,Bieze H,Veeger N,De Deyn PP

    更新日期：2015-04-06 00:00:00

  • Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.

    abstract：INTRODUCTION:MAPT encodes for tau, the predominant component of neurofibrillary tangles that are neuropathological hallmarks of Alzheimer's disease (AD). Genetic association of MAPT variants with late-onset AD (LOAD) risk has been inconsistent, although insufficient power and incomplete assessment of MAPT haplotypes ma...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt268

    authors： Allen M,Kachadoorian M,Quicksall Z,Zou F,Chai HS,Younkin C,Crook JE,Pankratz VS,Carrasquillo MM,Krishnan S,Nguyen T,Ma L,Malphrus K,Lincoln S,Bisceglio G,Kolbert CP,Jen J,Mukherjee S,Kauwe JK,Crane PK,Haines JL,

    更新日期：2014-07-01 00:00:00

  • Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.

    abstract：BACKGROUND:Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer's disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomar...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0545-5

    authors： Ashton NJ,Suárez-Calvet M,Heslegrave A,Hye A,Razquin C,Pastor P,Sanchez-Valle R,Molinuevo JL,Visser PJ,Blennow K,Hodges AK,Zetterberg H

    更新日期：2019-11-28 00:00:00

  • Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.

    abstract：BACKGROUND:Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune genes associated with late onset Alzheimer's disease (LOAD). Amongst these, a polymorphism in phospholipase C-gamma 2 (PLCG2) P522R has been reported to be protective against LOAD. PLC enzymes are key elements ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0469-0

    authors： Magno L,Lessard CB,Martins M,Lang V,Cruz P,Asi Y,Katan M,Bilsland J,Lashley T,Chakrabarty P,Golde TE,Whiting PJ

    更新日期：2019-02-02 00:00:00

  • Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria.

    abstract：BACKGROUND:[18F]FDG-PET hypometabolism patterns are indicative of different neurodegenerative conditions, even from the earliest disease phase. This makes [18F]FDG-PET a valuable tool in the diagnostic workup of neurodegenerative diseases. The utility of [18F]FDG-PET in dementia with Lewy bodies (DLB) needs further val...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0473-4

    authors： Caminiti SP,Sala A,Iaccarino L,Beretta L,Pilotto A,Gianolli L,Iannaccone S,Magnani G,Padovani A,Ferini-Strambi L,Perani D

    更新日期：2019-02-23 00:00:00